Driven Brands Faces Investor Investigation After Restatement of Financial Statements

GlobeNewswire Inc.GlobeNewswire Inc.
|||2 min read
Key Takeaway

Driven Brands faces investor investigation after restating financial statements due to material accounting errors in lease accounting, cash irregularities, and overstated expenses. Stock fell 30%.

Driven Brands Faces Investor Investigation After Restatement of Financial Statements

Driven Brands Holdings Inc. (NASDAQ: DRVN) is the subject of a securities investigation following significant accounting errors that prompted the company to delay its fourth-quarter earnings announcement. On February 25, 2026, the automotive services company disclosed material errors in its previously issued financial statements covering fiscal years 2023 and 2024, resulting in a sharp 30% decline in its stock price. The identified errors encompass lease accounting misstatements, cash account irregularities, and overstated expense figures.

In response to the accounting discrepancies, Driven Brands disclosed material weaknesses in its internal control environment, effectively invalidating the reliability of its financial statements and corresponding auditor reports for the affected periods. The company's decision to delay earnings reporting and acknowledge these control deficiencies raises questions about the adequacy of the company's financial reporting infrastructure and oversight mechanisms. The magnitude of the errors required formal restatement rather than routine corrections, underscoring the severity of the accounting issues identified.

Law firm Faruqi & Faruqi, LLP has initiated an investigation into potential securities law violations on behalf of investors who purchased Driven Brands shares during the period when the company was issuing the subsequently restated financial statements. The investigation examines whether company officials failed to disclose known accounting problems or material weaknesses in internal controls in a timely manner, which could constitute violations of securities regulations designed to protect investor interests.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 25

Related Coverage

GlobeNewswire Inc.

Weis Markets Faces Accounting Restatement, Stock Plunges as Law Firm Probes Securities Violations

Weis Markets restating financials for 2022-2024 due to overstated inventory; stock drops 7.16%. Law firm investigates potential securities law violations.

WMK
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR